A phase 2a study of adults with moderate-to-severe atopic dermatitis set out to determine if GBR 830, a first-in-class, humanized, monoclonal immunoglobulin G1 antibody, was safe and well tolerated.
Learn more at the Journal of the American Academy of Dermatology.